Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Nikita Shah Sells 146,403 Shares of Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Nikita Shah sold 146,403 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the sale, the executive vice president owned 253,390 shares of the company’s stock, valued at $4,436,858.90. This represents a 36.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $17.27 on Friday. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65. The business’s 50 day moving average is $17.15 and its two-hundred day moving average is $14.56. Amneal Pharmaceuticals, Inc. has a 12-month low of $9.15 and a 12-month high of $19.26. The stock has a market capitalization of $5.51 billion, a price-to-earnings ratio of 35.24 and a beta of 1.27.

Key Headlines Impacting Amneal Pharmaceuticals

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Amneal entered the second half of 2026 with higher guidance and a broader product pipeline, supporting the company’s growth outlook. However, erosion of its Rytary product remains a concern. Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
• Positive Sentiment: The Kashiv transaction gives Amneal an integrated biosimilars platform that could become a significant long-term growth engine, expanding its pipeline and commercial opportunities. Integration, regulatory execution and product adoption are key hurdles. Can Amneal’s Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
• Neutral Sentiment: Brokerages have a consensus price target of $17.67, indicating limited potential upside relative to recent trading levels and suggesting analysts see a fairly balanced risk-reward profile. Amneal Pharmaceuticals Receives $17.67 Consensus Price Target
• Neutral Sentiment: AMRX has rallied 44.8% over three months, but the advance now faces tests from upcoming earnings, new product launches and pipeline progress. Its higher valuation and Rytary revenue erosion could limit further gains. AMRX Stock Surges 44.8% in 3 Months
• Negative Sentiment: Amneal executives disclosed sizable stock sales. EVP Jason B. Daly sold 210,000 shares for approximately $3.65 million and an additional 6,613 shares, while EVP Nikita Shah sold 146,403 shares for approximately $2.56 million. The transactions substantially reduced their ownership stakes and may be weighing on investor sentiment, although insider sales do not necessarily indicate deteriorating fundamentals. Amneal Executive Stock Sale Filings

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Westshore Wealth LLC bought a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at approximately $13,833,000. Morgan Stanley grew its holdings in Amneal Pharmaceuticals by 37.5% in the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after buying an additional 1,315,018 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in Amneal Pharmaceuticals by 72.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock valued at $32,405,000 after acquiring an additional 1,069,400 shares during the period. Bank of New York Mellon Corp bought a new stake in Amneal Pharmaceuticals during the 2nd quarter valued at $17,573,000. Finally, Penn Capital Management Company LLC bought a new stake in Amneal Pharmaceuticals during the 4th quarter valued at $12,655,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on AMRX shares. UBS Group boosted their price objective on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Zacks Research raised Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Barclays boosted their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Finally, Weiss Ratings cut shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $17.67.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.